UAB 2242: A Prospective Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase IIb Study to Evaluate The Efficacy and Safety of Mocravimod as an Adjunctive and Maintenance Treatment in Adult Acute Myeloid Leukemia (AML) Patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (PKRPC001)


Awarded By

Total Award Amount

  • 1026950.00
  • Direct Costs

  • 789962.00
  • Sponsor Award Id

  • Contributor

  • Antonio Di Stasi M.D.   Principal Investigator  
  • Donna Salzman M.D.   Investigator  
  • Lauren Shea   Investigator  
  • Manuel Espinoza Gutarra   Investigator  
  • Omer Jamy   Investigator